Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study

  title={Pittsburgh compound B imaging and cerebrospinal fluid amyloid-$\beta$ in a multicentre European memory clinic study},
  author={Antoine Leuzy and Konstantinos Chiotis and Steen Gregers Hasselbalch and Juha O. Rinne and Alexandre de Mendonça and Markus Otto and Alberto Lle{\'o} and Miguel Castelo‐Branco and Isabel Santana and Jarkko Johansson and Sarah Anderl-Straub and Christine A. F. von Arnim and Ambros J Beer and Rafael Blesa and Juan Fortea and Sanna Kaisa Herukka and Erik Portelius and Josef Pannee and Henrik Zetterberg and Kaj Blennow and Agneta Nordberg},
  pages={2540 - 2553}
PET and CSF biomarkers of amyloid-β are considered interchangeable in defining ‘amyloid positivity’. However, Leuzy et al. report discordance between these measures in a multicentre memory clinic population. This suggests that in a minority of individuals these metrics may not be interchangeable, and may instead reflect distinct but interrelated processes. 

Figures and Tables from this paper

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
It is found that biomarker discordance allows for identification of individuals with elevated risk of progression toward fully abnormal amyloid-β biomarkers, with subsequent risk of neurodegeneration and cognitive decline.
AMYQ: An index to standardize quantitative amyloid load across PET tracers
The AMYQ index is a new MRI-independent index for standardizing and quantifying amyloid load across tracers and had excellent diagnostic performance to discriminate controls from patients with Alzheimer's disease (AD).
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
While biomarker agreement did not impact cognition in patients with dementia, discordant biomarkers are not benign in patients without dementia given their higher risk of clinical progression.
CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort
Amy-PET proved to be superior to CSF Aβ1–42 in terms of diagnostic accuracy for AD, with the possibility to further increase its specificity by focusing the analysis in specific areas such as the precuneus/posterior cingulate cortex and the striatum.
APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)‐derived peptides related to the amyloidogenic pathway, cortical thickness,
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.
The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale – Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment
This study aimed to investigate the accuracy of combined clinical markers in predicting amyloid‐PET status in mild cognitive impairment (MCI) individuals.
The Cerebrospinal Fluid Aβ1–42/Aβ1–40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer’s Disease in a Clinical Setting
An increased concordance is detected in the visual and quantitative (standardized uptake value ratio (SUVR) and total volume of distribution (VT)) [18F]AV45 PET measures when the CSF Aβ1–42/Aβ1-40 was applied compared to Aβ 1–42 alone.


Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography
It is shown that CSF amyloid-β 42 becomes abnormal beforeAmyloid PET and before neurodegeneration onset in preclinical Alzheimer’s disease, which has implications for risk factor interventions and future therapies.
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Analysis of agreement and disagreement between 2 biomarkers of β‐amyloid (Aβ) deposition in normal aging and dementia in a large multicenter study finds no agreement or disagreement between these biomarkers.
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans
Amyloid‐β42 (Aβ42) appears central to Alzheimer's disease pathogenesis and is a major component of amyloid plaques, and its decrease may reflect plaques acting as an Aβ42 “sink,” hindering transport of soluble A β42 between brain and CSF.
CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study
Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Cerebrospinal fluid Aβ42 analyzed consecutively in routine clinical practice at an accredited laboratory can be used with high accuracy to determine whether a patient has normal or increased cortical Aβ deposition and so can be valuable for the early diagnosis of Alzheimer disease.
Pittsburgh Compound-B and Alzheimer’s Disease Biomarkers in CSF, Plasma and Urine: An Exploratory Study
PIB retention is strongly related to CSF Aβ1–42, and to the numbers of the APOE Ε4 allele, and the relations between PIB uptake and other biomarkers of Alzheimer’s disease (AD).
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
The findings suggest that both biomarkers measure different aspects of AD Aβ pathology, and 4 different approaches in 2 different platforms converge on similar pathological Aβ cutoff levels; and different pipelines to process PET scans showed correlated but not identical results.
Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
BACKGROUND Two approaches are available for measuring Alzheimer's disease (AD) pathology in vivo. Biomarkers in cerebrospinal fluid (CSF) include amyloid-β1-42 (Aβ42) and tau. Furthermore, amyloid